These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 7831801

  • 1. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
    Benjouad A, Chapuis F, Fenouillet E, Gluckman JC.
    Virology; 1995 Jan 10; 206(1):457-64. PubMed ID: 7831801
    [Abstract] [Full Text] [Related]

  • 2. HIV type 1 V3 peptide constructs act differently on HIV type 1 infection of peripheral blood lymphocytes and macrophages.
    Benjouad A, Seddiki N, Ylisastigui L, Gluckman JC.
    AIDS Res Hum Retroviruses; 1997 Feb 10; 13(3):219-26. PubMed ID: 9115808
    [Abstract] [Full Text] [Related]

  • 3. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.
    Yahi N, Sabatier JM, Baghdiguian S, Gonzalez-Scarano F, Fantini J.
    J Virol; 1995 Jan 10; 69(1):320-5. PubMed ID: 7983725
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.
    Fantini J, Hammache D, Delézay O, Yahi N, André-Barrès C, Rico-Lattes I, Lattes A.
    J Biol Chem; 1997 Mar 14; 272(11):7245-52. PubMed ID: 9054420
    [Abstract] [Full Text] [Related]

  • 6. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N, Fantini J, Baghdiguian S, Mabrouk K, Tamalet C, Rochat H, Van Rietschoten J, Sabatier JM.
    Proc Natl Acad Sci U S A; 1995 May 23; 92(11):4867-71. PubMed ID: 7761414
    [Abstract] [Full Text] [Related]

  • 7. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.
    Burkly L, Mulrey N, Blumenthal R, Dimitrov DS.
    J Virol; 1995 Jul 23; 69(7):4267-73. PubMed ID: 7769687
    [Abstract] [Full Text] [Related]

  • 8. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.
    Yahi N, Fantini J, Mabrouk K, Tamalet C, de Micco P, van Rietschoten J, Rochat H, Sabatier JM.
    J Virol; 1994 Sep 23; 68(9):5714-20. PubMed ID: 8057453
    [Abstract] [Full Text] [Related]

  • 9. T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.
    Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T.
    J Virol; 1998 Dec 23; 72(12):9763-70. PubMed ID: 9811711
    [Abstract] [Full Text] [Related]

  • 10. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR, Strick N, Debnath AK.
    J Mol Recognit; 1995 Dec 23; 8(6):345-57. PubMed ID: 9052975
    [Abstract] [Full Text] [Related]

  • 11. Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages.
    Rabehi L, Seddiki N, Benjouad A, Gluckman JC, Gattegno L.
    AIDS Res Hum Retroviruses; 1998 Dec 20; 14(18):1605-15. PubMed ID: 9870313
    [Abstract] [Full Text] [Related]

  • 12. Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.
    Weinberg J, Liao HX, Torres JV, Matthews TJ, Robinson J, Haynes BF.
    AIDS Res Hum Retroviruses; 1997 May 20; 13(8):657-64. PubMed ID: 9168234
    [Abstract] [Full Text] [Related]

  • 13. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
    Mabrouk K, Van Rietschoten J, Rochat H, Loret EP.
    Biochemistry; 1995 Jul 04; 34(26):8294-8. PubMed ID: 7599121
    [Abstract] [Full Text] [Related]

  • 14. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.
    Yahi N, Sabatier JM, Nickel P, Mabrouk K, Gonzalez-Scarano F, Fantini J.
    J Biol Chem; 1994 Sep 30; 269(39):24349-53. PubMed ID: 7929093
    [Abstract] [Full Text] [Related]

  • 15. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
    Moulard M, Mabrouk K, Martin I, Van Rietschoten J, Rochat H, Sabatier JM.
    J Pept Res; 1999 Jun 30; 53(6):647-55. PubMed ID: 10408339
    [Abstract] [Full Text] [Related]

  • 16. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.
    Zanotto C, Calderazzo F, Dettin M, Di Bello C, Autiero M, Guardiola J, Chieco-Bianchi L, De Rossi A.
    Virology; 1995 Feb 01; 206(2):807-16. PubMed ID: 7856094
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Multiple effects of CD4 CDR3-related peptide derivatives showing anti-HIV-1 activity on HIV-1 gp120 functions.
    Ohki K, Kimura T, Jones IM, Morita F, Ikuta K.
    Vaccine; 1994 Mar 01; 12(4):343-50. PubMed ID: 8178557
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.